Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.

van Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM.

J Leukoc Biol. 2017 Oct;102(4):1017-1034. doi: 10.1189/jlb.5MR0217-059RR. Epub 2017 Jul 20. Review.

2.

Dendritic cell targeting vaccine for HPV-associated cancer.

Yin W, Duluc D, Joo H, Oh S.

Cancer Cell Microenviron. 2016;3(4). pii: e1482. Epub 2017 Jan 15.

3.

Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.

Yin W, Gorvel L, Zurawski S, Li D, Ni L, Duluc D, Upchurch K, Kim J, Gu C, Ouedraogo R, Wang Z, Xue Y, Joo H, Gorvel JP, Zurawski G, Oh S.

EBioMedicine. 2016 Jan 28;5:46-58. doi: 10.1016/j.ebiom.2016.01.029. eCollection 2016 Mar.

4.

Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies.

Lehmann CH, Heger L, Heidkamp GF, Baranska A, Lühr JJ, Hoffmann A, Dudziak D.

Vaccines (Basel). 2016 Mar 28;4(2). pii: E8. doi: 10.3390/vaccines4020008. Review.

5.

Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance.

Nirschl CJ, Anandasabapathy N.

Hum Vaccin Immunother. 2016;12(1):104-16. doi: 10.1080/21645515.2015.1066050. Review.

6.

Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses.

Clausen BE, Stoitzner P.

Front Immunol. 2015 Oct 22;6:534. doi: 10.3389/fimmu.2015.00534. eCollection 2015. Review.

7.

Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R.

Front Immunol. 2015 May 20;6:243. doi: 10.3389/fimmu.2015.00243. eCollection 2015. Review.

8.

Skin dendritic cells induce follicular helper T cells and protective humoral immune responses.

Yao C, Zurawski SM, Jarrett ES, Chicoine B, Crabtree J, Peterson EJ, Zurawski G, Kaplan DH, Igyártó BZ.

J Allergy Clin Immunol. 2015 Nov;136(5):1387-97.e1-7. doi: 10.1016/j.jaci.2015.04.001. Epub 2015 May 9.

9.

ESAT-6 Targeting to DEC205+ Antigen Presenting Cells Induces Specific-T Cell Responses against ESAT-6 and Reduces Pulmonary Infection with Virulent Mycobacterium tuberculosis.

Silva-Sánchez A, Meza-Pérez S, Flores-Langarica A, Donis-Maturano L, Estrada-García I, Calderón-Amador J, Hernández-Pando R, Idoyaga J, Steinman RM, Flores-Romo L.

PLoS One. 2015 Apr 27;10(4):e0124828. doi: 10.1371/journal.pone.0124828. eCollection 2015.

10.

Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases.

Lin CY, Lin SJ, Yang YC, Wang DY, Cheng HF, Yeh MK.

Hum Vaccin Immunother. 2015;11(3):650-6. doi: 10.1080/21645515.2015.1009345. Review.

11.

Host Langerin (CD207) is a receptor for Yersinia pestis phagocytosis and promotes dissemination.

Yang K, Park CG, Cheong C, Bulgheresi S, Zhang S, Zhang P, He Y, Jiang L, Huang H, Ding H, Wu Y, Wang S, Zhang L, Li A, Xia L, Bartra SS, Plano GV, Skurnik M, Klena JD, Chen T.

Immunol Cell Biol. 2015 Oct;93(9):815-24. doi: 10.1038/icb.2015.46. Epub 2015 Apr 1.

12.

Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.

Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar R, Fahmy TM, Edelson RL.

Int J Nanomedicine. 2014 Nov 12;9:5231-46. doi: 10.2147/IJN.S66639. eCollection 2014.

13.

Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors.

Stoitzner P, Schaffenrath S, Tripp CH, Reider D, Komenda K, Del Frari B, Djedovic G, Ebner S, Romani N.

Exp Dermatol. 2014 Dec;23(12):909-15. doi: 10.1111/exd.12573.

14.

Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.

He LZ, Weidlick J, Sisson C, Marsh HC, Keler T.

Cell Mol Immunol. 2015 Nov;12(6):719-28. doi: 10.1038/cmi.2014.100. Epub 2014 Oct 27.

15.

Targeting DNA vaccines to myeloid cells using a small peptide.

Ye C, Choi JG, Abraham S, Shankar P, Manjunath N.

Eur J Immunol. 2015 Jan;45(1):82-8. doi: 10.1002/eji.201445010. Epub 2014 Nov 2.

16.

A protective role of murine langerin⁺ cells in immune responses to cutaneous vaccination with microneedle patches.

Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2014 Aug 18;4:6094. doi: 10.1038/srep06094.

17.

Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance.

Flacher V, Tripp CH, Mairhofer DG, Steinman RM, Stoitzner P, Idoyaga J, Romani N.

EMBO Mol Med. 2014 Sep;6(9):1191-204. doi: 10.15252/emmm.201303283. Erratum in: EMBO Mol Med. 2014 Dec;6(12):1638.

18.

Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses.

Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, Dereuddre-Bosquet N, Zurawski S, Flamar AL, Oh S, Romain G, Chapon C, Banchereau J, Lévy Y, Le Grand R, Martinon F.

J Immunol. 2014 Sep 1;193(5):2416-26. doi: 10.4049/jimmunol.1303339. Epub 2014 Jul 23.

19.

Common polymorphisms in human langerin change specificity for glycan ligands.

Feinberg H, Rowntree TJ, Tan SL, Drickamer K, Weis WI, Taylor ME.

J Biol Chem. 2013 Dec 27;288(52):36762-71. doi: 10.1074/jbc.M113.528000. Epub 2013 Nov 11.

20.

C-type Lectin Receptors for Tumor Eradication: Future Directions.

Streng-Ouwehand I, Unger WW, Van Kooyk Y.

Cancers (Basel). 2011 Aug 8;3(3):3169-88. doi: 10.3390/cancers3033169.

Supplemental Content

Support Center